Global dysregulation of the chromosome 14q32 imprinted region in uterine carcinosarcoma

Devor,Eric  J.; De Mik,Jillian  N.; Ramachandran,Shyam; Goodheart,Michael  J.; Leslie,Kimberly  K.

doi:10.3892/etm.2012.458

Global dysregulation of the chromosome 14q32 imprinted region in uterine carcinosarcoma

Authors:
- Eric J. Devor
- Jillian N. De Mik
- Shyam Ramachandran
- Michael J. Goodheart
- Kimberly K. Leslie
View Affiliations

Affiliations: Department of Obstetrics and Gynecology, University of Iowa Carver College of Medicine, Iowa City, IA 52242, USA, Department of Pediatrics, University of Iowa Carver College of Medicine, Iowa City, IA 52242, USA
Published online on: January 25, 2012 https://doi.org/10.3892/etm.2012.458
Pages: 677-682

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Uterine carcinosarcoma (UCS) is a rare but very aggressive cancer of the female reproductive tract with an extremely poor prognosis. With the goal of understanding the role of microRNA (miRNA) dysregulation in these tumors, we profiled the expression of 667 human miRNAs in a panel of eight UCS patients and five benign control primary tissue samples. These expression profiles revealed two important characteristics of UCS. First, compared with the two most common uterine cancers, endometrial endometrioid adenocarcinoma and endometrial serous adenocarcinoma, UCS samples display a virtually unique pattern of miRNA dysregulation with an overlap of only 5% among the three tumor types. In addition, nearly one-third of the miRNAs significantly dysregulated in UCS tissues compared with benign endometrium (32 of 114) lie in a single small (250-kb) imprinted region of chromosome 14q32. These data suggest that the presence of such a global, region-specific disruption substantially contributes to the unique histology and poor outcome of this type of cancer.

View Figures

View References

1.	D'Angelo E and Prat J: Uterine sarcomas: A review. Gynecol Oncol. 116:131–139. 2010.
2.	Evans HL, Chawla SP, Simpson C and Finn KP: Smooth muscle neoplasms of the uterus other than ordinary leiomyoma. A study of 46 cases with emphasis on diagnostic criteria and prognostic factors. Cancer. 62:2239–2247. 1988. View Article : Google Scholar : PubMed/NCBI
3.	Kernochan LE and Garcia RL: Carcinosarcomas (malignant mixed Müllerian tumor) of the uterus: Advances in elucidation of biologic and clinical characteristics. J Natl Compr Canc Netw. 7:550–557. 2009.
4.	Zelmanowicz A, Hildesheim A, Sherman ME, et al: Evidence for a common etiology for endometrial carcinomas and malignant mixed mullerian tumors. Gynecol Oncol. 69:253–257. 1998. View Article : Google Scholar : PubMed/NCBI
5.	Silverberg SG, Major FJ, Blessing JA, et al: Carcinosarcoma (malignant mixed mesodermal tumor) of the uterus. A Gynecologic Oncology Group pathologic study of 203 cases. Int J Gynecol Pathol. 9:1–19. 1990. View Article : Google Scholar
6.	Sreenan JJ and Hart WR: A pathologic study of 29 metastatic tumors: Further evidence for the dominant role of the epithelial component and the conversion theory of histogenesis. Am J Surg Pathol. 19:666–674. 1995. View Article : Google Scholar : PubMed/NCBI
7.	Jin Z, Ogata S, Tamura G, et al: Carcinosarcomas (malignant mullerian mixed tumors) of the uterus and ovary: A genetic study with special reference to histogenesis. Int J Gynecol Pathol. 22:368–373. 2003. View Article : Google Scholar : PubMed/NCBI
8.	Wada H, Enomoto T, Fujita M, et al: Molecular evidence that most but not all carcinosarcomas of the uterus are combination tumors. Cancer Res. 57:5379–5385. 1997.PubMed/NCBI
9.	Abeln EC, Smit VT, Wessels JW, et al: Molecular genetic evidence for the conversion hypothesis of the origin of malignant mixed Müllerian tumors. J Pathol. 183:424–431. 1997.PubMed/NCBI
10.	Fujii H, Yoshida M, Gong ZX, et al: Frequent genetic heterogeneity in the clonal evolution of gynecological carcinosarcoma and its influence on phenotypic diversity. Cancer Res. 60:114–120. 2000.PubMed/NCBI
11.	Taylor NP, Zighelboim I, Huettner PC, et al: DNA mismatch repair and TP53 defects are early events in uterine carcinosarcoma tumorigenesis. Mod Pathol. 19:1333–1338. 2006. View Article : Google Scholar : PubMed/NCBI
12.	Melo SA and Esteller M: Dysregulation of microRNAs in cancer: Playing with fire. FEBS Lett. 585:2087–2099. 2011. View Article : Google Scholar : PubMed/NCBI
13.	Rovira C, Güida MC and Cayota A: MicroRNAs and other small silencing RNAs in cancer. IUBMB Life. 62:859–868. 2010. View Article : Google Scholar : PubMed/NCBI
14.	Kircher M, Bock C and Paulsen M: Structural conservation versus functional divergence of maternally expressed microRNAs in the Dlk1/Gtl2 imprinting region. BMC Genomics. 9:3462008. View Article : Google Scholar : PubMed/NCBI
15.	Guens E, De Temmerman N, Hilven P, et al: Methylation analysis of the intergenic differentially methylated region of DLK1-GTL2 in human. Eur J Hum Genet. 15:352–361. 2007. View Article : Google Scholar : PubMed/NCBI
16.	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-delta delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
17.	Guo W, Sarkar SK and Peddada SD: Controlling false discoveries in multidimensional directional decisions, with applications to gene expression data on ordered categories. Biometrics. 66:485–492. 2010. View Article : Google Scholar : PubMed/NCBI
18.	Devor EJ, Hovey AM, Goodheart MJ, Ramachandran S and Leslie KK: microRNA expression profiling of endometrial endometrioid adenocarcinomas and serous adenocarcinomas reveals profiles containing shared, unique and differentiating groups of microRNAs. Oncol Rep. 26:995–1002. 2011.
19.	Ratner ES, Tuck D, Richter C, et al: MicroRNA signatures differentiate uterine cancer tumor subtypes. Gynecol Oncol. 118:251–257. 2010. View Article : Google Scholar : PubMed/NCBI
20.	Castilla MA, Moreno-Bueno G, Romero-Perez L, et al: Micro-RNA signature of the epithelial-mesenchymal transition in endometrial carcinosarcoma. J Pathol. 223:72–80. 2011. View Article : Google Scholar : PubMed/NCBI
21.	Sengupta S, den Boon JA, Chen IH, et al: MicroRNA 29c is down-regulated in nasalpharyngeal carcinomas, up-regulating mRNAs encoding extracellular matrix proteins. Proc Natl Acad Sci USA. 105:5874–5878. 2008. View Article : Google Scholar : PubMed/NCBI
22.	Salvi A, Sabelli C, Moncini S, et al: MicroRNA-23b mediates urokinase and c-met downmodulation and a decreased migration of human hepatocellular carcinoma cells. FEBS J. 276:2966–2982. 2009. View Article : Google Scholar : PubMed/NCBI
23.	Cochrane DR, Spoelstra NS, Howe EN, Nordeen SK and Richer JK: MicroRNA-200c mitigates invasiveness and restores sensitivity to microtubule-targeting chemotherapeutic agents. Mol Cancer Ther. 8:1055–1066. 2009. View Article : Google Scholar : PubMed/NCBI
24.	Gregory P, Bert A, Paterson E, et al: The miR-200 family and miR-205 regulate epithelial to mesenchymal transition by targeting ZEB1 and SIP1. Nat Cell Biol. 10:593–601. 2008. View Article : Google Scholar : PubMed/NCBI
25.	Vrba L, Jensen TJ and Garbe JC: Role for DNA methylation in the regulation of miR-200c and miR-141 expression in normal and cancer cells. PLoS ONE. 5:e86972010. View Article : Google Scholar : PubMed/NCBI
26.	Dixon-McIver A, East P, Mein CA, et al: Distinctive patterns of microRNA expression associated with karyotype in acute myeloid leulaemia. PLoS ONE. 3:e21412008. View Article : Google Scholar : PubMed/NCBI
27.	Haller F, von Heydebreck A, Zhang JD, et al: Localization- and mutation-dependent microRNA (miRNA) expression signatures in gastrointestinal stromal tumours (GISTs), with a cluster of co-expressed miRNAs located at 14q32.31. J Pathol. 220:71–86. 2010. View Article : Google Scholar
28.	Micci F, Tiexeira MR, Haugom L, Abeler VM and Heim S: Genomic aberrations in carcinomas of the uterine corpus. Genes Chrom Cancer. 40:229–246. 2004. View Article : Google Scholar : PubMed/NCBI
29.	Salvesen HB, Carter SL, Mannelqvist M, et al: Integrated genomic profiling of endometrial carcinoma associates aggressive tumors with indicators of PI3 kinase activation. Proc Natl Acad Sci USA. 106:4834–4839. 2009. View Article : Google Scholar : PubMed/NCBI
30.	Seitz H, Royo H, Bortolin M-L, et al: A large imprinted microRNA gene cluster at the mouse Dlk1-Gtl2 domain. Genome Res. 14:1741–1748. 2004. View Article : Google Scholar : PubMed/NCBI
31.	Sánchez-Solana B, Nueda ML, Ruvira MD, et al: The EGF-like proteins DLK1 and DLK2 function as inhibitory non-canonical ligands of NOTCH1 receptor that modulate each other's activities. Biochim Biophys Acta. 1813:1153–1164. 2011.PubMed/NCBI